Boston-based Juniper Pharmaceuticals has elected Mary Ann Gray to its board of directors and appointed her as its audit committee chair.
Dr Gray has over 20 years of biotechnology and biopharmaceutical experience and is the owner and president of Gray Strategic Advisors as well as serving on the boards of Acadia Pharmaceuticals, Senomyx Inc. and TetraLogic Pharmaceuticals.
Prior to its acquisition by Shire earlier this year, Dr Gray was lead director at Dyax Corporation and has also held senior roles at the Federated Kaufmann Fund, GTC Biotherapeutics and Schering-Plough.
Jim Geraghty, Juniper’s chairman, said: “Mary Ann is a highly qualified corporate director and experienced audit committee chair, and we are very pleased to have her join Juniper’s board.
“Her unique blend of Wall Street, financial, and scientific experience will be a tremendous asset as Juniper continues to advance its clinical programs to drive long-term shareholder value.”
Gray succeeds Donald Hunter, who tendered his resignation from the board last year.
Geraghty added: “We deeply appreciate Don Hunter’s contributions during his tenure on Juniper’s board, and his willingness to provide continuity in his role as audit committee chair during our extensive search for the right person to succeed him.”